InsightfulValue
← Home

Paul Hartmann
Paul Hartmann

Healthcare & biotech / Medical and healthcare products


πŸ”§ Tools

βœ… Due Diligence
πŸ”₯ Video Insights

Paul Hartmann: A Healthcare Stock Down 20% – Is the Market Missing a Hidden Value Opportunity?

November 19, 2026

Paul Hartmann is approaching its 52-week low, and investors have a difficult question: is this a temporary setback or a warning sign? Trading around €187.50 as of November 18, 2026, the shares have fallen approximately 21% from their €238 high. The pressure comes from disappointing 2025 profitability, elevated operating costs, US tariffs and uncertainty surrounding German healthcare reimbursement reforms. Revenue, however, remained resilient, reaching approximately €2.46 billion in 2025. Net income declined significantly, while margins remain under pressure. There are encouraging developments. During the first half of 2026, Hartmann reported renewed organic revenue growth and improved adjusted operating earnings. Management maintained its full-year adjusted EBITDA forecast of €270–310 million. This suggests its transformation programme may be delivering results. The dividend remains €8 per share, unchanged since 2022, offering an indicated yield above 4% at the current share price. From a value-investing perspective, the low valuation, established market position and consistent dividend are attractive. However, regulatory uncertainty, weak historical earnings and rising costs could delay recovery. A sustained improvement in margins and earnings will be essential before investors regain confidence. Could this beaten-down healthcare stock surprise the market? This review is for informational and educational purposes only, not financial advice.

Paul Hartmann at €196: A 25% Drop Despite Rising Profits β€” Is This German Dividend Stock Undervalued?

October 12, 2026

Paul Hartmann shares have fallen to approximately €196, around 25% below their 52-week high of €260. Yet the latest financial results show improving profitability. Is the market overlooking a potential value opportunity, or are investors anticipating new challenges? The first half of 2026 delivered encouraging results. Revenue increased 3.3% to €1.252 billion, while adjusted earnings before interest, taxes, depreciation and amortization rose to €151.7 million, up €25.9 million year over year. The corresponding margin improved from 10.4% to 12.1%. Management confirmed its full-year forecast of moderate organic growth and adjusted earnings between €270 million and €310 million. So why is the stock struggling? Rising material, energy and transportation costs could pressure second-half earnings. Planned changes to German healthcare and long-term care regulations may also hurt performance in 2027. These concerns help explain why stronger results have not translated into a higher share price. For dividend investors, Hartmann offers consistency: the annual dividend has remained at €8 per share from 2021 through 2025. At €196, that represents a yield of approximately 4.1%. A recovery could follow if margins remain strong and costs stabilize. However, regulatory pressure, limited growth and low trading liquidity remain risks. The discount alone does not guarantee undervaluation. This review is for informational and educational purposes only, not financial advice.

Paul Hartmann: Defensive Business, Weak Investor Mood

May 7, 2026

Paul Hartmann has recently seen its stock price remain under pressure, reflecting weaker investor sentiment toward European healthcare and slower profitability growth. The current price suggests that expectations have become cautious, even though the company continues to operate in a stable and defensive market. Revenues have remained relatively resilient, while earnings have been affected by higher raw material, energy, and labor costs. Margins have improved slightly from recent lows but remain below historical levels. Dividends have historically been stable, supported by consistent cash generation and a conservative financial approach. The company continues focusing on efficiency measures and operational restructuring aimed at restoring profitability over time. However, risks include ongoing cost inflation, reimbursement pressure, and slower economic growth in Europe. From a value perspective, the stock may attract investors looking for a defensive business with long operating history and stable demand. The stock is down mainly because profitability recovery has been slower than expected. Recovery is possible if margins continue improving. This review is for informational and educational purposes only, not financial advice.
© 2024 - 2026 InsightfulValue.com. All rights reserved. Newsletter
Legal